Mucopolysaccharidosis (MPS) Treatment Market Share 2021: Global Trends, Key Players, Industry Analysis Report to 2027

The Global Mucopolysaccharidosis (MPS) Treatment Market is estimated to be valued at US$ 1,566.5 million in 2020 and is expected to exhibit a CAGR of 9% over the forecast period 2022-2028.

Mucopolysaccharides are a group of genetic disorders in which the body cannot properly break down mucopolysaccharides, the long-chain sugar molecules found in the body. As a result, these sugars can build up in your cells, blood, and connective tissue and cause a number of health problems. There are seven forms of mucopolysaccharidosis. In general, most of the people affected look healthy at birth and experience a decline in physical and/or mental function after a period of normal development. As the condition progresses, it can affect appearance, physical abilities, organ and system function, and, in most cases, cognitive development. The underlying genetic cause depends on the morphology. Most cases are inherited in an autosomal recessive manner, but one specific form (type II) follows an X-linked inheritance pattern. Treatment is based on each person’s signs and symptoms.

 

Market Segments

By Treatment

Enzyme Replacement Therapies
Stem Cell Therapies

By Type of MPS

MPS I
MPS II
MPS IV A
MPS VI
MPS VII

Key Players

Major players operating in the global mucopolysaccharidosis (MPS) treatment market include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.

Scope of the Report

The research study analyzes the global Mucopolysaccharidosis (MPS) Treatment industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

 

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Mucopolysaccharidosis (MPS) Treatment Market Report

1. What was the Mucopolysaccharidosis (MPS) Treatment Market size in 2019 and 2020; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Mucopolysaccharidosis (MPS) Treatment Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Mucopolysaccharidosis (MPS) Treatment Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.